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Introduction: This study evaluated the effects on blood pressure (BP) of valsartan 160 mg or 
losartan 100 mg addition to amlodipine 5 mg in hypertensive patients.
Methods: 221 patients with inadequately controlled BP (DBP  90 mmHg) after 4 weeks of 
treatment with amlodipine 5 mg were randomized to receive losartan/amlodipine combination 
therapy or valsartan/amlodipine combination therapy for 4 weeks in a cross-over study design. 
At the end of the wash-out period and of each treatment period, clinic and ambulatory BP 
measurements were recorded.
Results: 166 patients completed the study. Both combination treatments induced a greater 
ambulatory BP reduction than did monotherapy. However, the further mean reductions in BP 
versus monotherapy were significantly greater with the valsartan/amlodipine combination 
(SBP/DBP: –7.9 ± 3.4/–6.5 ± 2.6 mmHg for 24-hour, –8.0 ± 3.4/–6.6 ± 2.7 mmHg for daytime; 
–7.7 ± 3.3/–6.4 ± 2.7 mmHg for nighttime) than with the losartan/amlodipine combination 
(SBP/DBP: –5.5 ± 2.8/–4.2 ± 2.1 mmHg for 24-hour, –5.7 ± 2.9/–4.4 ± 2.2 mmHg for daytime; 
–4.8 ± 2.8/–3.7 ± 2.2 mmHg for nighttime; P  0.01 vs valsartan/amlodipine). The incidence 
of adverse events with valsartan/amlodipine (8%) and losartan/amlodipine (9%) was lower than 
that observed with amlodipine monotherapy (17%; P  0.05 vs combinations).
Conclusion: Valsartan 160 mg plus amlodipine 5 mg produced greater BP reductions than 
losartan 100 mg plus amlodipine 5 mg.
Keywords: angiotensin receptor blocker, ambulatory blood pressure monitoring, valsartan, 
losartan, amlodipine, combination therapy
Introduction
Current hypertension management guidelines advocate a blood pressure (BP) goal of 
140/90 mmHg in the general population with uncomplicated hypertension.1,2 Lower 
BP goals are recommended for high-risk patients, such as those with concomitant 
diabetes mellitus, renal disease, or evidence of other target organ damage. These 
recommendations are supported by evidence accumulated from long-term trials sug-
gesting that lower BP values are associated with better outcomes in a broad range of 
patients.3,4 Major studies have shown that most patients with hypertension need two 
or more antihypertensive drugs to achieve their BP goals, regardless of the medication 
chosen as initial therapy.5–8 Advantages of combination therapy include the following: 
(1) greater BP reduction and higher response rates than with monotherapy, probably 
caused by the simultaneous effect on several regulatory systems involved in abnormal 
BP elevation; (2) favorable alterations in pharmacokinetics; (3) fewer adverse effects Vascular Health and Risk Management 2010:6 88
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with consequent better tolerability and improved com-
pliance with treatment; and (4) possibly lower costs of 
treatment.9,10
Given the vast array of available antihypertensive agents, 
the number of potential combinations is large; however, 
rational choice must be based on the characteristics of each 
agent and their complementary mechanisms of action.9,10
Treatment guidelines suggest that the combination of an 
angiotensin receptor blocker (ARB) and a calcium channel 
blocker (CCB) provides an effective option for patients with 
hypertension.11
The use of these drugs in combination has the potential to 
achieve additive BP reduction by targeting multiple mecha-
nisms involved in BP regulation.12 ARBs that block the angio-
tensin II type 1 receptors act to promote vasodilation and 
sodium excretion.13 CCBs blocking calcium channels in vas-
cular smooth muscle cells thereby reduce peripheral vascular 
resistance.12 Targeting multiple systems has benefits in terms 
of overcoming potential counter-regulatory mechanisms, eg, 
the compensatory activation of the renin-angiotensin system 
induced by CCBs.12,14 Further, such a combination of drugs 
provides advantages in enhancing tolerability, in that ARBs 
prevent or attenuate some of the adverse events of CCBs, 
such as ankle edema and headache.15,16
Given the general validity of these pharmacodynamic 
considerations, the efficacy of the CCB/ARB combination 
must be assessed in a clinical setting, specifically compared 
with ARB monotherapy, because the different pharmacologic 
properties of the various ARBs might have an important 
clinical impact, and might produce different interactions 
with CCBs, with a consequent possible influence on clini-
cal efficacy.
The objective of this study was to evaluate the antihy-
pertensive effect, evaluated by ambulatory BP monitoring, 
of losartan 100 mg added to amlodipine 5 mg monotherapy 
compared with the addition of valsartan 160 mg to the same 
amlodipine dose in moderately hypertensive patients who 
were nonresponders to amlodipine monotherapy.
Patients and methods
This was a prospective, randomized, open-label, blinded end 
point (PROBE)17 evaluation, cross-over study. Consecutive 
outpatients of both sexes, aged 35 to 75 years, were eligible 
for recruitment if they had a sitting diastolic BP (DBP) of 
 99 mmHg and 110 mmHg at the end of an initial 2-week 
wash-out period. Patients with sitting DBP  110 mmHg 
or sitting systolic BP (SBP)  200 mmHg at the end of the 
washout period were excluded from the study, as were those 
with secondary or malignant hypertension, type 1 or type 2 
diabetes mellitus, myocardial infarction or cerebrovascular 
accident within the preceding 6 months, heart failure, clini-
cally significant valvular heart disease or arrhythmia, renal or 
hepatic insufficiency, pregnancy, or known hypersensitivity 
to the drugs used in the study.
The study protocol was approved by the local ethical 
committee and written informed consent was obtained from 
all patients before they were included in the study.
According to the study design, after a 2-week washout 
period, during which any previous antihypertensive therapy 
was discontinued, eligible patients were treated with amlo-
dipine 5 mg once daily for 4 weeks. Thereafter, the non-
responder patients (DPB  90 and/or SBP  140 mmHg) 
were randomized to receive either additional valsartan 
160 mg or losartan 100 mg for a further 4 weeks, with 
the additional therapies to be taken at the same hour in 
the morning (approximately between 8 am and 9 am) in 2 
cross-over periods, each separated by a 4-week amlodipine 
5 mg monotherapy period. At the end of each study period 
(placebo, monotherapy, or combination), BP was measured 
in both the clinic environment and through noninvasive 
ambulatory BP monitoring. Clinic BP was obtained with a 
standard mercury sphygmomanometer with the patient in 
the sitting position, 24 hours after last drug intake. Three 
measurements, taken at 2-minute intervals after 10 minutes 
of sitting, were averaged, and these averages were used as 
clinic BP reference values. Heart rate (HR) was measured 
after each BP measurement through the palpatory method 
at the radial artery level.
Ambulatory BP monitoring was performed over 24 hours 
with the use of a clinically validated device (Spacelabs 
90207 ambulatory BP monitor; Spacelabs Inc., Redmond, 
Washington, USA) that was programmed to measure BP 
every 15 minutes during the entire course of the recording. 
Each recording was started in the morning, immediately 
after clinic BP assessment and drug administration. Patients 
were instructed to remain motionless each time a reading 
was taken. Analysis of 24-hour BP recordings was preceded 
by removal of artefacts, according to previously described 
editing criteria.18 Recordings were considered valid when 
no more than 2 nonconsecutive hours were missing over 
24 hours. For each patient, the following data related to 
SBP, DBP, and HR were obtained through analysis of 
the recordings: 24-hour mean values, as well as daytime 
(7 am–11 pm), nighttime (11 pm–7 am), and hourly mean 
values. The trough-to-peak (T/P) ratio, computed after peak 
and trough changes were selected, was calculated for each Vascular Health and Risk Management 2010:6 89
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individual subject.19 To calculate peak changes, the clinician 
selected the hour in which maximal reduction in BP was 
noted after treatment between the second and eighth hours 
after drug administration and averaged this change with data 
from the immediately adjacent hour in which reduction was 
most evident. Trough BP changes were calculated by averag-
ing the last 2 hours of the recordings.19 Data were averaged 
(mean) for all patients.
The smoothness index (SI) was computed by dividing 
the average of the 24-hour BP changes after treatment by the 
corresponding standard deviation.20,21 This calculation has 
been shown to reflect whether treatment smoothly reduced 
BP during the 24-hour period more accurately than the T/P 
ratio.20,21
At each visit, adverse events spontaneously reported or 
elicited by indirect questioning were recorded.
Statistical analysis
All analyses were conducted with the SAS system, version 
6.12 (SAS Institute, Inc., Cary, North Carolina, USA). 
Analysis of variance was used for BP results. Differences in 
T/P ratios between treatments were evaluated with nonpara-
metric tests (univariate signed rank test), whereas the paired 
Student’s t test was used to assess differences in SI. The level 
of statistical significance was kept at 0.05. Data are shown 
as mean ± standard deviation (SD).
Results
A total of 233 consecutive outpatients with moderate 
hypertension who were referred to the hypertension center 
of our clinic were screened for eligibility. At the end of the 
wash-out period 221 patients (106 males and 115 females), 
aged 39 to 75 years, fulfilled the inclusion/exclusion criteria 
and were treated with amlodipine 5 mg once daily for 4 weeks. 
Table 1 Demographic and clinical characteristic of the study 
population
Total  
randomized
Completed  
the study
P
Total randomized 185 166 ns
Women/men 91/94 82/84 ns
Age y ± sD 59.1 ± 11.7 58.9 ± 11.6 ns
sBP, mmHg 169.8 ± 13.1 169.5 ± 13.0 ns
DBP, mmHg 104.1 ± 6.9 103.9 ± 6.8 ns
Heart rate, beats/min 75.8 ± 7.1 75.7 ± 7.1 ns
smoking habit, n (%) 41 (22.2 %) 36 (21.6 %) ns
Hypercholesterolemia, n (%) 53 (28.6 %) 47 (28.3 %) ns
ecg-LVH, n (%) 16 (8.6 %) 14 (8.4 %) ns
Table 2 Average 24-hour, daytime and nighttime ambulatory systolic blood pressure (sBP) and diastolic blood pressure (DBP) values 
of the randomized patients who completed the study (n = 166)
24-hour Daytime Nighttime
Baseline Amlodipine Combination Baseline Amlodipine Combination Baseline Amlodipine Combination
sBP, mmHg 152.3 ± 8.9 139.1 ± 5.8 +L 133.6 ± 5.3 157.9 ± 9.7 143.8 ± 5.6 138.1 ± 5.3 139.9 ± 9.3128.8 ± 7.9 +L 124.0 ± 7.2
+V 131.2 ± 5.5 135.8 ± 5.5 +V 121.1 ± 7.3
P (AnOVA-
between 
treatment)
0.01 0.01 0.01
P (AnOVA-  
vs baseline)
0.001 0.001 0.001 0.001 0.001 0.001
DBP, mmHg 91.5 ± 4.2 82.2 ± 5.2 +L 78.0 ± 5.8 95.2 ± 4.2 85.5 ± 5.2 +L 81.1 ± 5.8 81.7 ± 5.8 74.4 ± 6.6 +L 70.7 ± 6.7
+V 75.7 ± 5.9 +V 78.9 ± 6.0 +V 68.0 ± 6.8
P (AnOVA-
between 
treatment)
0.01 0.01 0.01
P (AnOVA-  
vs baseline)
0.001 0.001 0.001 0.001 0.001 0.001
Heart rate, 
beats/min
70.7 ± 6.8 71.1 ± 6.1 +L 70.7 ± 5.8 73.6 ± 7.4 74.2 ± 7.1 +L 73.8 ± 7.1 64.2 ± 5.5 65.1 ± 5.6 +L 64.6 ± 5.1
+V 70.5 ± 6.1 +V 73.6 ± 6.9 +V 64.2 ± 5.1
P (AnOVA-
between 
treatment)
0.201 0.384 0.424
Abbreviations: L, losartan;   V, valsartan.Vascular Health and Risk Management 2010:6 90
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Figure 1 Mean ambulatory sBP and DBP reduction induced by addition of val-
sartan or losartan to amlodipine in the randomized patients who completed the 
study (n = 166).
Basal Amlodipine Losartan/Amlodipine Valsartan/Amlodipine
Hour
S
B
P
 
(
m
m
H
g
)
D
B
P
 
(
m
m
H
g
)
Hour
175
160
145
130
115
100
8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 1 2 3 4 5 6 7
8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 1 2 3 4 5 6 7
115
100
85
70
55
Figure 2 Twenty-four-hour sBP and DBP after treatment with monotherapy (4 weeks) 
and after losartan or valsartan added to amlodipine (8 weeks) in the randomized 
patients who completed the study (n = 166).
One hundred eighty-five patients whose clinic BP was not ade-
quately controlled (DBP  90 mmHg and or SBP  140 mmHg) 
were admitted to the study and randomized to the cross-over 
design. Their main demographic and clinical characteristics 
are shown in the Table 1. They did not significantly differ 
from those of the 36 patients who normalized their BP with 
amlodipine monotherapy, with the exception of baseline SBP/
DBP levels, which were lower in these latter patients (158.6 ± 
10.4/101.2 ± 3.4 mmHg vs 169.8 ± 13.1/104.1 ± 6.9 mmHg in 
the nonnormalized patients). After randomization 19 patients 
dropped out (11 due to nonvalid ambulatory BP monitoring 
recording or intolerance to the device, 4 due to excessively high 
BP values and 4 were lost at follow-up), while 166 patients 
completed the study. The results presented here pertain to this 
latter group of patients.
Averaged 24-hour, daytime, and nighttime ambulatory 
SBP and DBP values are shown in Table 2. Amlodipine 
significantly reduced ambulatory BP values compared with 
baseline values: mean decreases in 24-hour, daytime, and 
nighttime SBP/DBP were: –13.2 ± 7.6/–9.3 ± 4.2 mmHg, 
–14.1 ± 7.9/–9.7 ± 4.8 mmHg, and –11.1 ± 6.8/–7.3 ± 
3.9 mmHg, respectively (all P  0.001). A further decrease in 
ambulatory BP was observed at the end of each combination 
treatment (Table 2). However, with the valsartan/amlodipine 
combination, the further mean reduction in BP (SBP/DBP: 
–7.9 ± 3.4/–6.5 ± 2.6 mmHg for 24-hour, –8.0 ± 3.4/–6.6 ± 
2.7 mmHg for daytime, and –7.7 ± 3.3/–6.4±2.7 mmHg for 
nighttime) was greater than that seen with the losartan/amlo-
dipine combination (SBP/DBP: –5.5 ± 2.8/–4.2 ± 2.1 mmHg 
for 24-hour, –5.7 ± 2.9/–4.4 ± 2.2 mmHg for daytime, and 
–4.8 ± 2.8/–3.7 ± 2.2 mmHg for nighttime); and the differ-
ence between the 2 treatments was statistically significant 
(P  0.01; Table 2 and Figure 1). Calculation of hourly 
averaged SBP and DBP values (Figure 2) showed that BP 
reduction attained with both combinations was more consis-
tent than that observed with amlodipine monotherapy, with 
no negative influence on the circadian BP profile.
Analysis of hourly profiles also confirmed that the BP 
reduction attained with the addition of valsartan to amlo-
dipine was greater than that attained with the addition of 
losartan to amlodipine, particularly at nighttime (Figure 3). 
The T/P ratio computed at the end of combination treatments 
was above the threshold of 0.5, which is universally regarded 
as clinically acceptable, however, it was significantly higher 
with the valsartan/amlodipine combination than with the 
losartan/amlodipine combination (P  0.05 for both SBP 
and DBP; Table 3). As with the T/P ratio, the average SI 
was higher with the valsartan/amlodipine combination than Vascular Health and Risk Management 2010:6 91
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Figure 3 Mean differences from monotherapy in hourly sBP and DBP values after 4 weeks of losartan or valsartan added to amlodipine in the randomized patients who 
completed the study (n = 166).
with the losartan/amlodipine combination (P  0.05 for 
SBP, P  0.01 for DBP; Table 3). Clinical BP data (Table 4) 
showed a significant reduction in SBP/DBP levels with amlo-
dipine monotherapy compared with baseline; this reduction 
was greater after combination treatments. Again, compared 
with amlodipine monotherapy, the changes in SBP and DBP 
values were significantly greater when valsartan was added to 
amlodipine than when losartan was added to amlodipine.
The rate of adverse events (9% with losartan/amlodipine 
and 8% with valsartan/amlodipine) was not significantly dif-
ferent between the 2 combinations, but was lower than the rate 
observed with amlodipine monotherapy (17%, P  0.05). The 
most frequent adverse events were ankle oedema (5.9% with 
losartan/amlodipine, 5.4% with valsartan/amlodipine and 12.6% 
with amlodipine alone), headache (2.1%, 2.6% and 3.6% respec-
tively), flushing (0.5%, 0.5% and 0.9%) and constipation (0.5%, 
0.5% and 0.4%). No serious adverse event was observed.
Discussion
The result of the present study indicate that, in patients with 
moderate hypertension, combination therapy with losartan 
100 mg/amlodipine 5 mg or valsartan 160 mg/amlodipine 
5 mg provides a clinically meaningful antihypertensive effect 
that is better than that attained with amlodipine monotherapy. 
This is consistent with findings from previous studies show-
ing that the addition of losartan22–23 or valsartan24,25 enhances 
the efficacy of amlodipine.
However, the BP decrease resulting from the addition of 
valsartan to amlodipine was significantly greater than that 
observed when losartan was added to amlodipine. This was 
Table 3 Mean values of trough/peak ratio and smoothed index 
after 4 weeks of treatment with losartan 100 mg/amlodipine 5 mg 
and valsartan 160 mg/amlodipine 5 mg
Losartan/ 
amlodipine
Valsartan/ 
amlodipine
P
Trough/peak ratio
  sBP 0.58 ± 0.24 0.65 ± 0.26 0.014
  DBP 0.60 ± 0.22 0.66 ± 0.23 0.015
smoothed index
  sBP 2.29 ± 1.21 2.62 ± 1.21 0.014
  DBP 2.15 ± 0.85 2.55 ± 0.97 0.01Vascular Health and Risk Management 2010:6 92
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Table 4 Mean ± sD clinical blood pressure and heart rate at baseline, after amlodipine monotherapy and after its combination with 
losartan or valsartan in the randomized patients who completed the study (n = 166)
Baseline Amlodipine Losartan/amlodipine Valsartan/amlodipine
sBP mmHg 169.5 ± 13.0 154.2 ± 6.5 148.2 ± 6.2 145.7 ± 6.1*
DBP mmHg 103.9 ± 6.8 94.1 ± 5.2 88.7 ± 4.8 84.4 ± 4.7*
Heart rate, beats/min 75.7 ± 7.1 76.6 ± 7.2 75.9 ± 7.1 75.8 ± 6.9
*P  0.05 vs losartan/amlodipine.
true for both SBP and DBP 24-hour mean values, as well as 
for daytime and nighttime mean values.
Such a difference in efficacy could be due to the different 
pharmacologic effect of the ARBs because of their different 
chemical structures and their different pharmacokinetic pro-
files. Losartan is an imidazole-derivative with a biphenyltetra-
zole side chain, while valsartan is a tetrazole-biphenyl-valine 
derivative and features only one heterocyclic structure; also, 
valsartan is an immediately active drug, whereas losartan 
needs to be converted into a more-active metabolite; and 
lastly losartan is metabolized while valsartan is excreted 
unchanged.26 The concept of the differing pharmacologic 
effects is supported by the demonstration that, in humans, the 
BP dose-response curves to exogenous angiotensin II with 
losartan pretreatment show a significant rightward shift only 4 
hours after drug ingestion, while, with valsartan pretreatment, 
the dose-response curves show a significant rightward shift 
both 4 and 24 hours after drug ingestion.27
No pharmacokinetic interactions have been demonstrated 
when amlodipine was administrated with valsartan.22 No 
data are available on the pharmacokinetics of the losartan/
amlodipine combination.
Clinical BP measurements confirmed that the antihyper-
tensive effect of the valsartan/amlodipine combination was 
superior to that of the losartan/amlodipine combination, 
and that the difference (–2.5 mmHg for SBP and –2 mmHg 
for DBP) was due to the greater add-on effect of valsartan 
compared with losartan.
Because a continuous and graded relationship exists 
between BP values and cardiovascular risk, lower BP val-
ues are associated with better outcomes in a broad range of 
patients.28,29 Therefore, from a clinical point of view, even a 
moderate decrease in BP has the potential to significantly 
reduce hypertension-related morbidity and mortality, particu-
larly in high-risk patients. Thus, for example, in the VALUE 
study30 apparentely minor differences in BP levels between 
amlodipine- and valsartan-treated patients resulted in a 
significantly different frequency of outcomes in hypertensive 
patients at high cardiovascular risk.
When the duration of hypotensive action was evaluated 
over 24 hours, the T/P ratios for SBP and DBP obtained 
with both the combinations given once daily fulfilled United 
States Food and Drug Administration guidelines for efficacy 
(T/P ratio  50%); however, the ratio was greater with 
valsartan/amlodipine than with losartan/amlodipine. The 
SI, which provides information about the homogeneity of 
the antihypertensive effect,20,21 also showed significantly 
higher values for both SBD and DBP with the valsartan/
amlodipine combination. Greater T/P ratios and SI values 
reflect less variability in BP, which has been demonstrated 
to have an independent effect on organ damage and disease 
prognosis.31
The losartan/amlodipine and valsartan/amlodipine 
combinations also were well tolerated, with a comparable 
incidence of adverse events between the 2 treatments, and 
these incidence rates were lower than the rate observed with 
amlodipine monotherapy. Most adverse events were of mild 
or moderate intensity. This is consistent with the proven 
tolerability profiles of ARBs when administered alone or in 
combination with CCBs.
Conclusion
In spite of study limitations due to the open study design and 
the relatively short duration of treatment, the findings of the 
present study indicate that the addition of valsartan 160 mg 
to amlodipine 5 mg produces greater ambulatory and clinic 
BP reductions than the addition of losartan 100 mg to the 
same dose of amlodipine, and this outcome probably reflects 
the different pharmacodynamic profiles of the 2 ARBs. 
These results suggest that –– at least when this low dose of 
amlodipine is used –– combination with valsartan might offer 
some advantage in terms of better BP response, which is of 
clinical relevance in high-risk hypertensive patients.
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